Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cardiff Oncology (CRDF) Capital Expenditures (2016 - 2025)

Cardiff Oncology's Capital Expenditures history spans 15 years, with the latest figure at $700000.0 for Q4 2025.

  • For Q4 2025, Capital Expenditures rose 975.0% year-over-year to $700000.0; the TTM value through Dec 2025 reached $744000.0, changed N/A, while the annual FY2025 figure was $744000.0, N/A changed from the prior year.
  • Capital Expenditures for Q4 2025 was $700000.0 at Cardiff Oncology, up from $38000.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $902000.0 in Q1 2025 and bottomed at -$896000.0 in Q2 2025.
  • The 5-year median for Capital Expenditures is $80000.0 (2024), against an average of $117533.3.
  • The largest annual shift saw Capital Expenditures crashed 1100.0% in 2024 before it surged 1027.5% in 2025.
  • A 5-year view of Capital Expenditures shows it stood at $205000.0 in 2021, then crashed by 111.22% to -$23000.0 in 2022, then skyrocketed by 134.78% to $8000.0 in 2023, then plummeted by 1100.0% to -$80000.0 in 2024, then soared by 975.0% to $700000.0 in 2025.
  • Per Business Quant, the three most recent readings for CRDF's Capital Expenditures are $700000.0 (Q4 2025), $38000.0 (Q3 2025), and -$896000.0 (Q2 2025).